ARS Pharmaceuticals, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $37.7 million (+16.0% year over year) and diluted EPS of -$0.36. It usually reports 36–68 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 8, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Mar 9, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–68 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
From press release
|
Q3 FY2026
ended Sep 30, 2026
|
38
+16.0%
|
-36
+30.4%
|
-0.36
+30.8%
|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
34
+114.2%
|
-62
-38.9%
|
-0.63
-37.0%
|
|
May 15, 2026
45 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
23
+184.5%
|
-61
-78.6%
|
-0.61
-74.3%
|
|
Mar 9, 2026
68 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
28
-67.6%
|
-41
-182.8%
|
-0.42
-199.5%
|
|
Nov 10, 2025
41 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
33
+1471.6%
|
-51
-167.4%
|
-0.52
-160.0%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
16
+3043.4%
|
-45
-258.6%
|
-0.46
-253.8%
|
|
May 14, 2025
44 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
8
|
-34
-229.8%
|
-0.35
-218.2%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
87
|
50
+796.6%
|
0.42
+662.5%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPRY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671858
- Former names
- Silverback Therapeutics, Inc. (until Nov 8, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.